On the other hand, the FDA has approved pembrolizumab in combination with chemotherapy for high-risk early-stage TNBC patients, irrespective of tumor PD-L1 expression, based on the promising results from the KEYNOTE-522 trial [60]. The gene discussed is CD274; the disease is neoplasm.